Earnings Releases

TOMI Environmental Solutions, Inc. reported the year ended December 31, 2025 results: revenue $5,636,000, net income $(3,749,000), EPS ($0.19) per basic and diluted share.

“deformed wing virus (DWV) for agricultural biosecurity in honeybees. Financial Results for the year ended December 31, 2025, compared to December 31, 2024 · Sales, net was $5,636,000 compared to $7,739,000 for the years ended December 31, 2025 and 2024, respectively. This was primarily driven by customers deferring capital expenditure projects due to the”

NIKE, Inc. reported financial results for the fiscal quarter ended February 28, 2026.

“Today NIKE, Inc. issued a press release disclosing financial results for the fiscal quarter ended February 28, 2026.”

HERSHEY CO updated its fiscal year 2026 guidance (reaffirmed).

“The Hershey Company is reaffirming its net sales, organic sales and earnings per share guidance for fiscal year 2026.”

MCCORMICK & CO INC updated its first quarter ended February 28, 2026 guidance (reaffirmed).

“On March 31, 2026 the Registrant issued a press release and held a conference call with analysts to report on the results of operations for the first quarter for fiscal year 2026, which ended on February 28, 2026. Furnished with this Form 8-K as Exhibit 99.1 is a copy of the press release labeled " McCormick Reports Strong First Quarter Performance and Reaffirms 2026 Outlook," which includes an unaudited Cons olidated Income Statement for the three months ended February 28, 2026, an unaudited Consolidated Balance Sheet of the Registrant as of February 28, 2026, and an unaudited Consolidated Cash Flow Statement for the three months ended February 28, 2026.”

READING INTERNATIONAL INC reported financial results for year and quarter ended December 31, 2025.

“On March 31, 2026, Reading International, Inc. (the “Company”) issued a press release announcing information regarding its results of operations and financial condition for the year and quarter ended December 31, 2025, a copy of which is attached as Exhibit 99.1.”

FIRST KEYSTONE CORP reported the quarter and year ended December 31, 2025 results: net income $6,152,000, EPS $0.99.

“Net income for the year ended December 31, 2025 was $6,152,000. Net income per share was $0.99”

AMERICAN SHARED HOSPITAL SERVICES reported financial results for the fourth quarter ended December 31, 2025.

“On March 31, 2026, American Shared Hospital Services (the “Company”) issued a press release announcing its financial results for the fourth quarter and year-end 2025.”

Imunon, Inc. reported financial results for the year ended December 31, 2025.

“IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025”

PVH CORP. /DE/ reported Full year 2026 results: EPS $11.80 to $12.10. Guidance initiated.

“Provided its 2026 outlook. Stefan Larsson, Chief Executive Officer, commented, “We delivered a strong fourth quarter and finish to the year”

PVH CORP. /DE/ reported Full year 2025 results: revenue $8.950 billion, EPS $11.40.

“translation ◦ Inventory: Increased 5% to $1.583 billion compared to the prior year, including a 4% impact from increased tariffs. • 2025 full year: ◦ Revenue: Increased 3% to $8.950 billion compared to the prior year period, in line with guidance of up low single-digits. Increased less than 1% on a constant currency basis, in line with guidance of flat to increase”

PVH CORP. /DE/ reported Fourth quarter 2025 results: revenue $2.505 billion, EPS $3.82.

“basis –– underscoring our next level PVH+ Plan execution and the strength of our global iconic brands.” Key Highlights • 2025 fourth quarter: ◦ Revenue: Increased 6% to $2.505 billion compared to the prior year period and exceeded guidance of increase slightly to up low single-digits. Flat on a constant currency basis and exceeded guidance of a slight”

DAWSON GEOPHYSICAL CO reported year ended December 31, 2025 results: revenue revenues of $75.6 million, net income net loss of $1.9 million, EPS $0.06 per common share.

“December 31, 2025, compared to Adjusted EBITDA of $0.9 million in the quarter ended December 31, 2024. ​ For the year ended December 31, 2025, the Company reported revenues of $75.6 million, an increase of 2% compared to $74.2 million for the year ended December 31, 2024. Revenue included reimbursable revenue of $13.7 million and $20.7 million for the years ended”

DAWSON GEOPHYSICAL CO reported fourth quarter and year ended December 31, 2025 results: revenue revenues of $27.0 million, net income net income of $0.6 million, EPS $0.02 per common share.

“For the fourth quarter ended December 31, 2025, the Company reported revenues of $27.0 million, an increase of 72% compared to $15.6 million for the comparable quarter ended December 31, 2024.”

Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.

“Net revenues for the year ended December 31, 2025 were $12.5 million”

AgEagle Aerial Systems Inc. reported financial results for the quarter and full year ended December 31, 2025.

“On March 31, 2026, AgEagle Aerial Systems, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025, and provided a company update.”

SOLESENCE, INC. reported the twelve months ended December 31, 2025 results: revenue $62.1 million, net income $1.8 million.

“Revenue for the twelve months ended December 31, 2025, was a record $62.1 million compared to $52.3 million, a 19% increase over the same period in 2024. Gross profit for the twelve months ended December 31, 2025, was $16.1 million compared to $16.2 million over the same period in 2024. Gross margin for the twelve months ended December 31, 2025, was 26%, compared to 31% for same period in 2024. Net income for the twelve months ended December 31, 2025, was $1.8 million compared to $4.2 million in the same period in 2024.”

SOLESENCE, INC. reported the fourth quarter ended December 31, 2025 results: revenue $12.5 million, net income approximately $0.2 million.

“Revenue for the fourth quarter was $12.5 million, compared to $12.6 million for the same period in 2024. Gross profit increased to $3.4 million in the fourth quarter, compared to $2.8 million for the same period in 2024. Gross margin in the fourth quarter was 27%, compared to 22% for the same period in 2024. Net income in the fourth quarter was approximately $0.2 million, compared to a net loss of approximately $0.6 million for the same period in 2024.”

CPI AEROSTRUCTURES INC reported financial results for the quarter and year ended December 31, 2025.

“On March 31, 2026 CPI Aerostructures, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025.”

VOLITIONRX LTD reported full fiscal year 2025 results: revenue $1.7 million.

“Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.”

374Water Inc. reported the full year ended December 31, 2025 results: revenue $0.2 million.

“with clear operational milestones, commercial traction, strategic relationships, and execution.” 2025 Financial Summary · For the year ended December 31, 2025, revenue totaled $0.2 million, compared to $0.4 million in the prior year. The $0.2 million decrease in revenue is primarily due to a decrease in equipment revenue of $1.9 million offset by an increase in”

SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.

“For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The”

SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.

“to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s”

Ainos, Inc. reported financial results for year ended December 31, 2025.

“On March 30, 2026, Ainos, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”

Presidio Property Trust, Inc. reported the year ended December 31, 2025 results: revenue approximately $16.8 million, net income approximately $10.5 million, or $8.59 per basic and diluted share.

“share for the year ended December 31, 2024. The change in net income attributable to the Company’s common stockholders was a result of: ● Total revenue was approximately $16.8 million for the year ended December 31, 2025 compared to approximately $18.9 million for the same period in 2024, a decrease of approximately $2.1 million or 11.2%. As of December 31,”

INTELLINETICS, INC. reported three months ended December 31, 2025 results: revenue $4,323,843, net income net loss of $207,975, EPS ($0.05) per basic and diluted share.

“Intellinetics for more consistent performance and long-term value creation.” Summary – 2025 Fourth Quarter Results Revenues for the three months ended December 31, 2025 were $4,323,843, an increase of 1.0%, as compared with $4,280,071 for the same period in 2024. This increase was primarily due to an 8.4% increase in SaaS revenue, partially offset by a 1.8%”

INTELLINETICS, INC. reported fiscal year ended December 31, 2025 results: revenue $16,583,446, net income net loss of $1,872,895, EPS ($0.44) per basic and diluted share.

“Financial Highlights ● SaaS revenue increased 11.3% year over year to $6.3 million. ● Professional services revenue decreased 18.7% year over year. ● Total revenue was $16.6 million, reflecting lower professional services activity. ● Gross profit decreased 3.7% year over year, a function of volume, and gross profit margin increased 295 basis points due to”

VerifyMe, Inc. reported financial results for for the year and quarter ended December 31, 2025.

“On March 30, 2026, VerifyMe, Inc. (the “Company”) issued a press release to report financial results for the year and quarter ended December 31, 2025.”

CBAK Energy Technology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $58.80 million.

“Net revenues for the fourth quarter of 2025 were $58.80 million, representing a 131.8% increase compared to $25.37 million in the fourth quart”

CBAK Energy Technology, Inc. reported the full year ended December 31, 2025 results: revenue $195.19 million.

“pricing cycle has powerfully rebounded, acting as a critical counter-cyclical stabilizer for the Company’s consolidated top line. ● Full Year Consolidated Net Revenues reached $195.19 million, representing an 11% increase compared to $176.61 million in the fiscal year 2024. This top-line growth was primarily driven by a robust recovery in the battery raw materials”

Bio Green Med Solution, Inc. reported fourth quarter and year ended December 31, 2025 results: net income Net loss for the three months and year ended December 31, 2025, was $0.6 million and $3.0 million.

“announcing certain financial results for the fourth quarter and year ended December 31, 2025”

HireQuest, Inc. reported the full year ended December 31, 2025 results: revenue $30.6 million, net income $6.3 million, EPS $0.45 per diluted share.

“Total revenue was $30.6 million compared to $34.6 million in full year 2024, a decrease of 11.4%.”

HireQuest, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $7.0 million, net income $1.6 million, EPS $0.11 per diluted share.

“Total revenue in the fourth quarter of 2025 was $7.0 million compared to $8.1 million in the prior year period, a decrease of 13.0%.”

Prairie Operating Co. reported the year ended December 31, 2025 results: revenue $241.6 million.

“filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ef20068429_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Prairie Operating Co. Announces Year End 2025 Results • 2025 total revenue of $241.6 million (approximately $315.0 million including Bayswater), an increase of approximately 3,000% year-over-year • Record Adjusted EBITDA (1) of $155.5 million (approximately $220.0”

Phreesia, Inc. reported the fiscal fourth quarter and fiscal year ended January 31, 2026 results: revenue $127.1 million, net income $1.3 million.

“relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights • Total revenue was $127.1 million in the quarter, up 16% year-over-year. • Average number of healthcare services clients ("AHSCs") was 4,658 in the quarter, up 7% year-over-year. • Total revenue per AHSC was”

PDS Biotechnology Corp reported the year ended December 31, 2025 results: net income approximately $34.5 million, EPS $0.74 per basic and diluted share.

“Full Year 2025 Financial Results Net loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and diluted share for the year ended December 31, 2024.”

Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

“Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights.”

Presurance Holdings, Inc. reported financial results for the year ended December 31, 2025.

“On March 27, 2026, Presurance Holdings, Inc. (the "Company") publicly announced results for the fourth quarter of 2025. A copy of the Company's news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”

Presurance Holdings, Inc. reported financial results for the fourth quarter ended December 31, 2025.

“On March 27, 2026, Presurance Holdings, Inc. (the "Company") publicly announced results for the fourth quarter of 2025. A copy of the Company's news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.”

Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.

“Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.”

Annexon, Inc. reported financial results for the fourth quarter and the year ended December 31, 2025.

“On March 30, 2026, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2025.”

Beeline Holdings, Inc. reported fourth quarter ended December 31, 2025 results: revenue $2.5 million.

“Beeline Holdings, Inc. (Nasdaq: BLNE), the emerging digital mortgage lender and fractional equity platform, today announces financial results for the fourth quarter ended December 31, 2025. Q4 2025 Financial Highlights ● Net revenue of $2.5 million, up 127% year-over-year and 8.3% sequentially”

Pacific Coast Oil Trust reported January 2026 results: revenue approximately $2.0 million.

“The Current Month’s distribution calculation for the Developed Properties reflected operating income of approximately $182,000, as revenues from the Developed Properties were approximately $2.0 million, lease operating expenses including production taxes were approximately $1.8 million, and development costs were approximately $0.”

Tempest Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, EPS $6.33.

“from the RDO in June, $3.8 million from the November Offering and $2.8 million from Tempest’s at-the-market offering program. • Net loss and net loss per share for the year were $26.3 million and $6.33, respectively, compared to $41.8 million and $19.50, respectively, for the same period in 2024. • Research and development expenses for the year were $12.6 million”

RenovoRx, Inc. reported fiscal year ended December 31, 2025 results: revenue $1.1 million.

“For the year ending December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the device and repeat orders from existing customers.”

OXBRIDGE RE HOLDINGS Ltd reported the three months and year ended December 31, 2025 results: net income Net income for the quarter ended December 31, 2025 was $120,000, or $0.02 basic and diluted income per share; Net loss f.

“On March 30, 2026, Oxbridge Re Holdings Limited issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”

PAVmed Inc. reported financial results for year ended December 31, 2025.

“PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”

PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.

“For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.”

zSpace, Inc. reported the fiscal quarter and year ended December 31, 2025 results: revenue $4.8 million, net income ($7.3) million.

“Revenue in the fourth quarter of 2025 was $4.8 million compared to $8.5 million in the fourth quarter of 2024.”

Virgin Galactic Holdings, Inc reported the fourth quarter and full year ended December 31, 2025 results: revenue Revenue of $0.3 million, net income Net loss of $63 million.

“Quarter 2025 Financial Highlights • Cash position remains strong, with cash, cash equivalents and marketable securities of $338 million as of December 31, 2025. • Revenue of $0.3 million, compared to $0.4 million in the fourth quarter of 2024, attributable to access fees related to future astronauts. • GAAP total operating expenses of $61 million, compared to $82”

Ensysce Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 30, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025.”